Endothelial function in patients with rheumatologic diseases
https://doi.org/10.18705/1607-419X-2015-21-2-168-180
Abstract
Background. Сardiovascular diseases and their complications occupy one of the leading positions among causes of death in patients with rheumatologic diseases (RD), though the precise underlying mechanisms explaining fast progression of cardiovascular diseases are unknown. Early onset and high progression rate of atherosclerosis are the most common features, which cannot be fully explained by traditional cardiovascular risk factors. Inflammation, which is present in all RD and is involved in the pathogenesis of atherosclerosis, may contribute to the development of cardiovascular complications. Evaluation of the association between inflammation and endothelial dysfunction (an early predictor of atherosclerosis) may facilitate the understanding this mechanism. The objective of our study was to assess endothelial function in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), ankylosing spondylitis (AS) and rheumatoid arthritis (RA) and to evaluate the significance of various markers of endothelial dysfunction (ED), depending on the type of RD. Design and methods. The study enrolled 213 patients with various RD, 63 patients with ≥ 2 cardiovascular risk factors without RD and 10 healthy volunteers. Markers of endothelial dysfunction — homocysteine, asymmetric dimethylarginine (ADMA), endothelin 1–21, vascular cell adhesion molecule 1, 1sVCAM-1; intercellular adhesion molecule 1, sICAM-1 — and reactive hyperemia index (EndoPat 2000, Itamar Medical) were assessed in all patients. Results. The profile of ED markers differs in various RD, however, the most universal indicator is the ADMA level, especially in autoimmune RD with circulating autoantibodies (SLE, RA, SSc).
About the Authors
A. L. Maslyanskiy
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Research Department for Rheumatology, Federal North-West Medical Research Centre;
N. E. Zvartau
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, Senior Researcher, Department of Hypertension Pathogenesis and Management, Research Department for Hypertension, Federal North-West Medical Research Centre;
E. P. Kolesova
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, Researcher, Laboratory of Epidemiology of Hypertension, Research Department for Hypertension, Federal NorthWest Medical Research Centre
E. N. Bezkishky
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, Senior Researcher, North-Western Centre of Evidence-Based Medicine;
I. A. Shevchuk
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, Senior Researcher, North-Western Centre of Evidence-Based Medicine;
E. Yu. Vasilieva
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
Head, Clinical and Diagnostic Laboratory, Federal North-West Medical Research Centre;
V. I. Mazurov
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, DMSc, Professor, Academician of Russian Academy of Sciences, Honoured Scientists of Russian Federation, Principal Academic Secretary of the Presidium of North-West Department of Russian Academy of Sciences, Head, Research Laboratory of Rheumatology, Federal North-West Medical Research Centre;
A. O. Konradi
Federal North-West Medical Research Centre, St Petersburg, Russia
Russian Federation
Russian Federation
MD, PhD, MDSc, Professor, Deputy Director General, Head, Research Department for Hypertension, Federal North-West Medical Research Centre
References
1. Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol. 2011;27(2):174–182.
2. Shoenfeld Y, Gerli R, Doria A, Matsuura E, Cerinic MM, Ronda N et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation. 2005;112(21):3337–3347.
3. Doria A, Pauletto P. The heart in systemic autoimmune diseases. Amsterdam, London. Elsevier; 2004. 260 р.
4. Svenungsson E, Jensen-Urstad K, Heimburger M, Silveira A, Hamsten A, de Faire U et al. Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation. 2001;104 (16):1887–1893.
5. Frostegard J. Rheumatic diseases: insights into inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30 (5):892–893.
6. Szekanecz Z, Koch AE. Vascular involvement in rheumatic diseases: vascular rheumatology. Arthritis Res Ther. 2008;10 (5):224.
7. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23(5):581–590.
8. Bijlsma JWJ. EULAR compendium on rheumatic diseases. London: Br Med J Publishing; 2009.
9. Hudson M, Steele R, Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum. 2007;37 (2):93–98.
10. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105–1187.
11. Bonetti PO, Pumper GM, Higano ST, Holmes DRJr, Kuvin JT, Lerman A et al. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44(11):2137–2141.
12. Dunn OJ. Multiple contrasts using rank sums. Technometrics. 1964;5:241–252.
13. Bodnar N, Kerekes G, Seres I, Paragh G, Kappelmayer J, Nemethne ZG et al. Assessment of subclinical vascular disease associated with ankylosing spondylitis. J Rheumatol. 2011;38 (4):723–729.
14. Sari I, Okan T, Akar S, Cece H, Altay C, Secil M et al. Impaired endothelial function in patients with ankylosing spondylitis. Rheumatology (Oxford). 2006;45(3):283–286.
15. Erre GL, Sanna P, Zinellu A, Ponchietti A, Fenu P, Sotgia S et al. Plasma asymmetric dimethylarginine (ADMA) levels and atherosclerotic disease in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol. 2011;30(1):21–27.
16. Turiel M, Atzeni F, Tomasoni L, de Portu S, Delfino L, Bodini BD et al. Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. Rheumatology (Oxford). 2009;48(7):834–839.
17. Bultink IE, Teerlink T, Heijst JA, Dijkmans B, Voskuyl A. Raised plasma levels of asymmetric dimethylarginine are associated with cardiovascular events, disease activity, and organ damage in patients with systemic lupus erythematosus. Ann Rheum Dis.2005;64(9):1362–1365.
18. Kemeny-Beke A, Gesztelyi R, Bodnar N, Zsuga J, Kerekes G, Zsuga M et al. Increased production of asymmetric dimethylarginine (ADMA) in ankylosing spondylitis: association with other clinical and laboratory parameters. Joint Bone Spine. 2011;78(2):184–187.
19. Sobczak A, Goniewicz ML, Szoltysek-Boldys I. ADMA and SDMA levels in healthy men exposed to tobacco smoke. Atherosclerosis. 2009;205(2):357–359.
20. Siervo M, Bluck LJ. In vivo nitric oxide synthesis, insulin sensitivity, and asymmetric dimethylarginine in obese subjects without and with metabolic syndrome. Metabolism. 2012;61 (5):680–688.
21. Kaprove RE, Little AH, Graham DC, Rosen P. Ankylosing spondylitis: survival in men with and without radiotherapy. Arthritis Rheum. 1980;23(1):57–61.
22. Lehtinen K. Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis. 1993;52(3):174–176.
23. Surdacki A, Martens-Lobenhoffer J, Wloch A, Gluszko P, Rakowski T, Dubiel E et al. Plasma asymmetric dimethylarginine is related to anticitrullinated protein antibodies in rheumatoid arthritis of short duration. Metabolism. 2009;58(3):316–318.
24. Dimitroulas T, Sandoo A, Veldhuijzen van Zanten JJ, Smith J, Hodson J, Metsios G, et al. Predictors of asymmetric dimethylarginine levels in patients with rheumatoid arthritis: the role of insulin resistance. Scand J Rheumatol. 2013;42(3):176–181.
25. Kwasny-Krochin B, Gluszko P, Undas A. Plasma asymmetric dimethylarginine in active rheumatoid arthritis: links with oxidative stress and inflammation. Pol Arch Med Wewn. 2012;122(6):270–276.
26. Klimek E, Skalska A, Kwasny-Krochin B, Surdacki A, Sulicka J, Korkosz M et al. Differential associations of inflammatory and endothelial biomarkers with disease activity in rheumatoid arthritis of short duration. Mediators Inflamm. 2014;2014:681–635.
27. Blaise S, Maas R, Trocme C, Kom G, Roustit M, Carpentier P et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J Rheumatol. 2009;36(5):984–988.
28. Korkosz M, Gasowski J, Surdacki A, Leszczyński P, Katarzyna Pawlak-Bus, Sławomir Jeka et al. Disparate effects of anti-TNF-alpha therapies on measures of disease activity and mediators of endothelial damage in ankylosing spondylitis. Pharmacol Rep. 2013;65(4):891–897.
29. Cobanoglu AK, Gungor O, Kircelli F, Altunel E, Asci G, Ozbek S et al. Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplant patients. Int Urol Nephrol. 2013;45(5):1463–1469.
30. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S. Serum soluble adhesion molecules sICAM-1, sVCAM-1, sE-selectin in patients with systemic rheumatoid arthritis. Pol Merkur Lekarski. 2004;17 (100):353–356.
31. Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S, Ciolkiewicz M. A study on vascular endothelial growth factor and endothelin-1 in patients with extra-articular involvement of rheumatoid arthritis. Clin Rheumatol. 2006;25(3):314–319.
32. Constans J, Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. 2006;368 (1–2):33–47.
33. Gustafsson JT, Simard JF, Gunnarsson I, Pettersson S, Moller S, Fei GZ et al. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther. 2012;14(2): R46.
34. Pizarro S, Monarrez Espino J, Ruiz A, Jara LJ, Nava A, Riebeling-Navarro C. Soluble vascular cell adhesion molecule-1 indicates SLE disease activity and specific organ involvement. Rev Alerg Mex. 2007;54(6):189–195.
35. Wei JC, Jan MS, Yu CT, Huang YC, Yang CC, Tsou HK et al. Plasma homocysteine status in patients with ankylosing spondylitis. Clin Rheumatol. 2007;26(5):739–742.
36. Caramaschi P, Martinelli N, Biasi D, Carletto A, Faccini G, Volpe A et al. Homocysteine plasma concentration is related to severity of lung impairment in scleroderma. J Rheumatol. 2003;30 (2):298–304.
Review
For citations:
Maslyanskiy A.L., Zvartau N.E., Kolesova E.P., Bezkishky E.N., Shevchuk I.A., Vasilieva E.Yu., Mazurov V.I., Konradi A.O. Endothelial function in patients with rheumatologic diseases. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2015;21(2):168-180. (In Russ.) https://doi.org/10.18705/1607-419X-2015-21-2-168-180
Views:
1246
Email this article 